Streetbeat News

Analyst Ratings

TITN

Stephens & Co. analyst Daniel Imbro has reiterated an Overweight rating on Titan Machinery (NASDAQ:TITN) and maintained a price target of $42.

Portfolio Pulse from Benzinga Newsdesk

January 12, 2024 | 4:55 pm

SUM

Stephens & Co. analyst Trey Grooms has reiterated an Overweight rating on Summit Materials (NYSE:SUM) and maintained a $45 price target on the company's stock.

Portfolio Pulse from Benzinga Newsdesk

January 12, 2024 | 4:47 pm

TFX

RBC Capital analyst Shagun Singh has maintained an Outperform rating on Teleflex (NYSE:TFX) and increased the price target from $228 to $272.

Portfolio Pulse from Benzinga Newsdesk

January 12, 2024 | 4:32 pm

MRNA

RBC Capital analyst Luca Issi has reiterated an Outperform rating on Moderna (NASDAQ:MRNA) and maintained a price target of $125.

Portfolio Pulse from Benzinga Newsdesk

January 12, 2024 | 4:28 pm

SOPH

RBC Capital analyst Conor McNamara has reiterated an Outperform rating on Sophia Genetics (NASDAQ:SOPH) and maintained a price target of $8.

Portfolio Pulse from Benzinga Newsdesk

January 12, 2024 | 4:25 pm

ZM

Piper Sandler analyst James Fish has maintained a Neutral rating on Zoom Video Communications (NASDAQ:ZM) and increased the price target from $69 to $72.

Portfolio Pulse from Benzinga Newsdesk

January 12, 2024 | 4:04 pm

TWLO

Piper Sandler analyst James Fish upgraded Twilio Inc (NYSE:TWLO) from Neutral to Overweight and raised the price target from $75 to $82. The upgrade is based on four reasons: potential for higher free cash flows, emerging catalysts including a potential business split and marketing improvements, improving inputs for 2024 revenues, and the opportunity to own a top CPaaS business at a reasonable multiple. Twilio's stock rose 3.55% to $74.36 following the news.

Portfolio Pulse from Priya Nigam

January 12, 2024 | 4:02 pm

XRAY

Piper Sandler analyst Jason Bednar has maintained a Neutral rating on Dentsply Sirona (NASDAQ:XRAY) and increased the price target from $31 to $35.

Portfolio Pulse from Benzinga Newsdesk

January 12, 2024 | 4:02 pm

MMSI

Merit Medical Systems (NASDAQ:MMSI) received varied analyst ratings in the last quarter, with an average 12-month price target of $93.00, up from the previous $88.75. Analysts from Piper Sandler, Canaccord Genuity, Barrington Research, and Needham have adjusted their price targets and ratings, reflecting changes in market conditions and company performance. Merit Medical Systems, a medical equipment company, shows strong financial health with a positive revenue trend, high net margin, and efficient debt management, despite lagging behind industry peers in revenue growth.

Portfolio Pulse from Benzinga Insights

January 12, 2024 | 4:01 pm

FIVN

Five9 (NASDAQ:FIVN) has received diverse analyst ratings over the past three months, with 11 analysts offering opinions ranging from bullish to bearish. The average 12-month price target is $88.45, with a high of $100.00 and a low of $77.00, marking a 2.27% decrease from the previous average. Analysts have adjusted their ratings and price targets, with some maintaining and others raising or lowering their stance. Five9's financial performance shows a revenue growth of 16.01% but trails behind industry peers, with a net margin of -8.87%, ROE of -4.29%, ROA of -1.43%, and a high debt-to-equity ratio of 1.61.

Portfolio Pulse from Benzinga Insights

January 12, 2024 | 4:00 pm